Titre:
  • Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.
Auteur:Fernández-Cuesta, Lynnette; Oakman, Catherine; Falagan-Lotsch, Priscila; Smoth, Ke-Seay; Quinaux, E; Buyse, Marc; Dolci, Stella; Azambuja, Evandro; Hainaut, Pierre; Dell'orto, Patrizia; Larsimont, Denis; Francis, P; Crown, John; Piccart-Gebhart, Martine; Viale, Giuseppe; Leo, Angelo; Olivier, Magali
Informations sur la publication:Breast cancer research, 14, 3, page (R70)
Statut de publication:Publié, 2012
Sujet CREF:Cancérologie
MeSH keywords:Adenocarcinoma -- drug therapy -- genetics -- pathology
Adolescent
Adult
Aged
Antineoplastic Agents -- therapeutic use
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Apoptosis -- drug effects
Base Sequence
Breast Neoplasms -- drug therapy -- genetics -- pathology
Chemotherapy, Adjuvant
Disease-Free Survival
Doxorubicin -- therapeutic use
Female
Genes, p53
Humans
Ki-67 Antigen -- metabolism
Lymphatic Metastasis -- genetics
Middle Aged
Mutation, Missense
Receptor, erbB-2 -- metabolism
Receptors, Estrogen -- metabolism
Receptors, Progesterone -- metabolism
Retrospective Studies
Sequence Analysis, DNA
Sequence Deletion
Survival Analysis
Taxoids -- therapeutic use
Tumor Suppressor Protein p53 -- genetics
Young Adult
Note générale:Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:1465-5411
info:doi/10.1186/bcr3179
info:pii/bcr3179
info:scp/84861530773
info:pmid/22551440
PMC3446332